Diagnostic Potential of Circulating CXCL13, CXCL14, and CXCL16 in Colorectal Cancer: A Preliminary Case-Control Study.
4 affiliations
- 1Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-089 Bialystok, Poland.
- 2Department of Biochemical Diagnostics, University Clinical Hospital in Bialystok, 15-276 Bialystok, Poland.
- 3Department of Biochemical Diagnostics, Medical University of Bialystok, 15-089 Bialystok, Poland.
- 4Oncology Center of Bialystok, 15-027 Bialystok, Poland.
Abstract
Introduction: Epidemiological trends indicate that the global colorectal cancer (CRC) mortality will surpass 2.2 million deaths annually by the year 2050; therefore, the identification of novel circulating indicators that may support CRC diagnosis remains an important area of research. Objectives: The diagnostic relevance of circulating chemokines in CRC remains insufficiently understood. This study aimed to evaluate the diagnostic potential of selected serum C-X-C motif chemokines, CXCL13, CXCL14, and CXCL16, and to compare their diagnostic utility with CEA. Patients and Methods: This study included 62 individuals: 42 patients with CRC and 20 healthy volunteers. Serum chemokines levels were measured using a multiplex bead-based immunoassay (Luminex), and CEA levels via chemiluminescent microparticle immunoassay (CMIA). Results: Significant differences between patients with CRC and healthy controls were observed for serum CXCL13 concentrations. Spearman's analysis revealed a significant negative correlation between CXCL13 and CXCL14. CXCL14 showed the highest diagnostic sensitivity among the chemokines, similar to CEA, while combining CXCL13 or CXCL14 with CEA further increased sensitivity. CXCL13 showed the highest positive predictive value (PPV) among all tested proteins, while its negative predictive value (NPV) and diagnostic accuracy (ACC) exceeded those of CXCL14 and CXCL16. CXCL13 demonstrated the highest AUC among the investigated chemokines and remained independently associated with CRC status in multivariable analysis. CXCL13 combined with CEA yielded the numerically highest overall AUC, although the improvement over CEA alone was not statistically significant. Conclusions: CXCL13 serves as a valuable complementary biomarker, providing crucial additive insights that might augment diagnostic frameworks of patients with CRC. These findings support further evaluation of chemokines as potential adjuncts to established diagnostic biomarkers in larger, independent screening-like study cohorts.
Related
- Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases
- An exploratory study of circulating cell-free mRNAs across colorectal cancer stages
- Circulating Tumor DNA (ctDNA) for Minimal Residual Disease (MRD) Detection in Colorectal Cancer (CRC): Current Evidence, Clinical Applications, and Future Directions.
- Consensus and controversy of liquid biopsy using circulating tumour DNA (ctDNA) for molecular residual disease detection in colorectal cancer
- Photon Absorption Remote Sensing Virtual Histopathology: A Preliminary Exploration of Diagnostic Equivalence to Gold-Standard H&E Staining in Skin Cancer Excisional Biopsies
BibTeX
@article{romanowicz2026diagnostic,
title = {{Diagnostic Potential of Circulating CXCL13, CXCL14, and CXCL16 in Colorectal Cancer: A Preliminary Case-Control Study.}},
author = {Adrianna Romanowicz and Marta Łukaszewicz-Zając and Agnieszka Kulczyńska-Przybik and Kamil Safiejko and Marcin Juchimiuk and Barbara Mroczko},
journal = {Cancers},
year = {2026},
month = sep,
doi = {10.3390/cancers18193153},
url = {https://europepmc.org/article/MED/42882848},
note = {CC BY},
}
RIS
TY - JOUR
TI - Diagnostic Potential of Circulating CXCL13, CXCL14, and CXCL16 in Colorectal Cancer: A Preliminary Case-Control Study.
AU - Adrianna Romanowicz
AU - Marta Łukaszewicz-Zając
AU - Agnieszka Kulczyńska-Przybik
AU - Kamil Safiejko
AU - Marcin Juchimiuk
AU - Barbara Mroczko
PY - 2026
DA - 2026/09/29
JO - Cancers
DO - 10.3390/cancers18193153
UR - https://europepmc.org/article/MED/42882848
AB - Introduction: Epidemiological trends indicate that the global colorectal cancer (CRC) mortality will surpass 2.2 million deaths annually by the year 2050; therefore, the identification of novel circulating indicators that may support CRC diagnosis remains an important area of research. Objectives: The diagnostic relevance of circulating chemokines in CRC remains insufficiently understood. This study aimed to evaluate the diagnostic potential of selected serum C-X-C motif chemokines, CXCL13, CXCL14, and CXCL16, and to compare their diagnostic utility with CEA. Patients and Methods: This study included 62 individuals: 42 patients with CRC and 20 healthy volunteers. Serum chemokines levels were measured using a multiplex bead-based immunoassay (Luminex), and CEA levels via chemiluminescent microparticle immunoassay (CMIA). Results: Significant differences between patients with CRC and healthy controls were observed for serum CXCL13 concentrations. Spearman's analysis revealed a significant negative correlation between CXCL13 and CXCL14. CXCL14 showed the highest diagnostic sensitivity among the chemokines, similar to CEA, while combining CXCL13 or CXCL14 with CEA further increased sensitivity. CXCL13 showed the highest positive predictive value (PPV) among all tested proteins, while its negative predictive value (NPV) and diagnostic accuracy (ACC) exceeded those of CXCL14 and CXCL16. CXCL13 demonstrated the highest AUC among the investigated chemokines and remained independently associated with CRC status in multivariable analysis. CXCL13 combined with CEA yielded the numerically highest overall AUC, although the improvement over CEA alone was not statistically significant. Conclusions: CXCL13 serves as a valuable complementary biomarker, providing crucial additive insights that might augment diagnostic frameworks of patients with CRC. These findings support further evaluation of chemokines as potential adjuncts to established diagnostic biomarkers in larger, independent screening-like study cohorts.
SN - 2072-6694
ER -